Mbx Biosciences Inc (MBX) - News Archive

MBX Biosciences, a biopharmaceutical innovator specializing in precision peptide therapies, is positioned at the forefront of endocrine and metabolic disorder treatments. This article discusses the upcoming topline resu...

Advancement in Hypoparathyroidism Treatment: MBX Biosciences’ Phase 2 Avail Trial of MBX 2109 Concludes Enrollment MBX Biosciences has reached a significant milestone in the development of its promising treatment for hy...

In the evolving landscape of biopharmaceuticals, MBX Biosciences, Inc. (NASDAQ: MBX) continues to assert its commitment to addressing unmet medical needs through strategic leadership appointments and groundbreaking clin...

In a significant development for the treatment of hypoparathyroidism (HP), MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company, presented compelling data concerning the rationale and design o...

CARMEL, Ind. Sept. 16, 2024 MBX Biosciences, Inc. (Nasdaq: MBX) has successfully concluded its previously announced upsized initial public offering (IPO), closing the sale of 11,730,000 shares of its common stock at a p...